EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first ...

EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first patient has been treated in a phase I/II PULS Trial sponsored ...

All rights reserved. Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP. A Charity, Not for Profit. Company Limited by Guarantee. Registered in England No.

A new blood test to detect cancer at an early stage has shown promising results, according to a study, as scientists aim to ...

Prostate cancer imaging developed by university researchers has shown “extremely encouraging” results in its first clinical ...

A pancreatic cancer diagnosis is almost always serious, but symptoms often aren’t noticeable until the disease is in the ...

Yale researchers are sifting through a mosaic of cells in a living animal—both normal cells and mutated cells—to better ...

Detecting malignant cells is a crucial first step in improving health outcomes for the approximately 2 million Americans ...

RenovoRx, Inc. ("RenovoRx" or the "Company") , a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today ...

The new test has demonstrated an initial 94% sensitivity rate in tumour detection and the test is delivered in under 20 ...

Following stage separation, the booster landed on the SpaceX drone ship A Shortfall of Gravitas in the Atlantic Ocean roughly ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...